跳轉至內容
Merck
全部照片(1)

重要文件

R7757

Sigma-Aldrich

红细胞裂解缓冲液Hybri-Max

Liquid, sterile-filtered, suitable for hybridoma

同義詞:

RBC裂解缓冲液

登入查看組織和合約定價


About This Item

分類程式碼代碼:
12352207
NACRES:
NA.75
暫時無法取得訂價和供貨情況

產品名稱

红细胞裂解缓冲液Hybri-Max, liquid, sterile-filtered, suitable for hybridoma

無菌

sterile-filtered

品質等級

形狀

liquid

技術

cell culture | hybridoma: suitable

雜質

endotoxin, tested

應用

建议在细胞颗粒中加入1 mL缓冲液(细胞颗粒=1个脾脏或1-2亿个细胞)。 轻轻混合1分钟。 用15-20mL培养基活盐溶液稀释该缓冲液。 在250-500 × g 离心7分钟并弃去上清。 细胞可被稀释并准备计数或融合。 如果裂解不完全,可重复1-4步。

生化/生理作用

红细胞裂解缓冲液已被开发用于杂交瘤实验中,用于在融合前从小鼠脾细胞悬液中去除红细胞。 在需要从细胞悬液(如全血)中去除红细胞的体系中,它也很有用。

成分

含8.3 g/L 氯化铵的0.01 M Tris-HCl 缓冲液。

其他說明

注:本品用于去除小鼠红细胞。 本品可能不适用于其他动物红细胞的裂解。 该产品在小鼠脾细胞以外的任何应用场合的适用性必须由研究人员确定。

法律資訊

Hybri-Max is a trademark of Sigma-Aldrich Co. LLC

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

nwg

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Jolieke G van Oosterwijk et al.
The Journal of clinical investigation, 128(1), 369-380 (2017-12-12)
Oncogenic addiction to the Fms-like tyrosine kinase 3 (FLT3) is a hallmark of acute myeloid leukemia (AML) that harbors the FLT3-internal tandem duplication (FLT3-ITD) mutation. While FLT3 inhibitors like sorafenib show initial therapeutic efficacy, resistance rapidly develops through mechanisms that
John M Furgason et al.
Mutagenesis, 29(5), 341-350 (2014-08-12)
Next generation sequencing has become a powerful tool in dissecting and identifying mutations and genomic structural variants that accompany tumourigenesis. Sequence analysis of glioblastoma multiforme (GBM) illustrates the ability to rapidly identify mutations that may affect phenotype. Approximately 50% of
Iris Boraschi-Diaz et al.
Cytotechnology, 68(1), 105-114 (2014-09-24)
Osteoclasts are responsible for physiological bone remodeling as well as pathological bone destruction in osteoporosis, periodontitis and rheumatoid arthritis, and thus represent a pharmacological target for drug development. We aimed to characterize and compare the cytokine-induced osteoclastogenesis of bone marrow
H Guan et al.
Oncogenesis, 4, e166-e166 (2015-09-08)
Recent advances have highlighted profound roles of FOXO transcription factors, especially FOXO1, in bone development and remodeling. The regulation of bone development by FOXOs seems to be stage-specific or context dependent. FOXOs promote maintenance and differentiation of early progenitors of
Prabhat K Purbey et al.
Immunity, 47(3), 421-434 (2017-09-21)
Environmental insults are often detected by multiple sensors that activate diverse signaling pathways and transcriptional regulators, leading to a tailored transcriptional output. To understand how a tailored response is coordinated, we examined the inflammatory response elicited in mouse macrophages by

Questions

1–5 of 5 Questions  
  1. What is the Department of Transportation shipping information for this product?

    1 answer
    1. Transportation information can be found in Section 14 of the product's (M)SDS.To access the shipping information for this material, use the link on the product detail page for the product.

      Helpful?

  2. Is the BSA standard supplied with Product B6916, Bradford Reagent?

    1 answer
    1. No, we do not supply the BSA standard with this reagent. We recommend using one of the following products: Protein Standard (BSA) Solution, (2 mg/mL), Product No. P0834 or Protein Standard (BSA) Solution, (1 mg/mL), Product No. P0914, if lower concentrations of protein are to be measured.

      Helpful?

  3. Can Product R7757, Red Blood Cell Lysing Buffer Hybri-Max™, be used to lyse cells that are trapped in whole tissue preparations?

    1 answer
    1. Unfortunately, we have not verified the suitability of this lysis buffer for using with tissue samples and do not have a protocol.

      Helpful?

  4. Since you do not recommend Product R7757, Red Blood Cell Lysing Buffer Hybri-Max™, for treating whole blood, what protocol and products do you recommend for red cell lysis in a sample of whole blood?

    1 answer
    1. The following is a suggested protocol:1. Centrifuge to remove plasma. A volume of 0.2 mL of whole blood will yield approximately 0.1 mL of packed cells. Add 0.1ml of 1X buffer such as HBSS (Hanks' balanced salt solution, Product No. H1641) or DPBS (Dulbecco's phosphate buffered saline solution, Product No. D1283), to 0.1 mL of the pelleted cells and resuspend the pellet.2. Add 1-2 mls of 0.1X diluent (or water) and quickly mix cells using the same pipette.3. After 15 seconds, quickly add a volume of 2X diluent in the amount used in step 2 and mix thoroughly.  Dilute further with 1X diluent.  Wash cells once with buffer.

      Helpful?

  5. In step 3 of your usage sheet for Product R7757, Red Blood Cell Lysing Buffer Hybri-Max™, you say to dilute this buffer with medium or "salt solution". What salt solution is appropriate?

    1 answer
    1. Any balanced salt solution such as DPBS (Dulbecco's phosphate buffered saline) or HBSS (Hank's Balanced Salt Solution) may be used to dilute the buffer when following this procedure.

      Helpful?

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務